Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7623066 in advanced solid tumors
NCT05240898Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2021
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of RO7623066 in solid tumor (advanced stage) (5 arms), sponsored by Roche. Primary endpoint: Maximum Tolerated Dose. Started Aug 2021; status: completed.
02
Drugs
RO7623066
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05240898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05240898.